“…Immediately after purification, neutrophils were suspended at 5 ϫ 10 6 /ml in RPMI-1640 medium supplemented with 10% low endotoxin fetal bovine serum [Ͻ0.06 EU/ml by Limulus amoebocyte lysate (LAL) assay, BioWhittaker, Verviers, Belgium], treated with or without 1000 U/ml IFN-␣ (Roferon, Roche Laboratories, Nutley, NJ), 1000 U/ml IFN- (Betaferon, Schering AG, Berlin, Germany), or 200 U/ml IFN-␥ (R&D Systems, Minneapolis, MN), unless otherwise specified, and then, usually plated in 24-well tissue-culture wells (Orange, Trasadingen, Switzerland). After 20 h of incubation, cultures were usually stimulated for an additional 4 h (unless otherwise indicated) with the following substances: TNF-␣ (0.5-5 ng/ml; Peprotech, Rocky Hill, NJ), LPS (0.1-100 ng/ml, from Escherichia coli, serotype 026:B6, Sigma Chemical Co., St. Louis, MO), fMLP (10 -1000 nM, Sigma Chemical Co.), 60 g/ml insoluble IC prepared as described previously [32], and hsp Gp96 (1-50 g/ml, Immatics Biotechnologies GmbH, Tubingen, Germany). The levels of contaminating endotoxin in the Gp96 preparations (declared by Immatics Biotechnologies GmbH as Ͻ0.026 EU/g by LAL assay and equivalent to Ͻ0.1 ng/ml LPS) had no effect on TRAIL release.…”